Finance entity
Every one of those 1 sits in a single category, markets. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Jun 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, markets. Eli Lilly is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. The 7 average consequence score is above the beat benchmark of 6.5 in the same window. Retatrutide appears in 1 tracked Finance story from March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 72 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Retatrutide. Shared-story counts are live from our verified record — not editorial picks.
RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market.
Retatrutide is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
